Abstract: An ultraviolet ray protection agent including a compound having an ultraviolet ray protection effect as an active ingredient. The compound is expressed by general formula I?: wherein X represents NH or O; Y? represents a vinyl group substituted by a methyl group or a phenyl group, or a phenyl group substituted by a methoxy group or a fluorine atom, or a naphthyl group; and Z represents a phenyl group substituted by a methyl group, a carboxyl group or a nitro group, or a naphthyl group. The compound represented by the general formula I? includes both novel compounds of the present invention and known compounds. The ultraviolet ray protection agent of the present invention offers outstanding ultraviolet ray protection effectiveness and is very safe.
Abstract: Compounds including 1-(biphenyl-4-yl)methyl-1H-1,2,4-triazoles and 1-(biphenyl-4-yl)methyl-4H-1,2,4-triazoles each having a (2,4-dioxopyrrolidine-5-ylidene) methyl or (2,4-dioxo-tetrahydrofuran-5-ylidene)methyl group as the substituent at the 2′-position and salts thereof are lowly toxic and highly safe and are useful as an angiotensin II antagonist. Thus, these compounds can be used in medicines, which contain these compounds as an active ingredient.
Abstract: Novel stereoisomeric indole compounds of the formula (1), a process for the preparation the same, and use thereof
wherein, Y represents the group
wherein, X represents alkyl group having 1-5 carbon atom(s) (the alkyl group may be substituted with hydroxyl group, carboxyl group, amino group, methylthio group, mercapto group, guanidyl group, imidazolyl group or benzyl group), and R1 and R2 represent each independently hydrogen atom, alkyl group, aralkyl group, cycloalkyl group or aryl group;R represents hydrogen atom, alkyl group, aralkyl group, cycloalkyl group, aryl group, monovalent metal, amine or ammonium; and the symbol ‘*’ represents a position of an asymmetric carbon atom.
Abstract: An antiviral agent comprising as an active ingredient a phorbol derivative of formula (I):
(wherein R1, R2, R3, R4, and R5, independently one another, represent a hydrogen atom, an aliphatic carboxylic acid residue, or an aromatic carboxylic acid residue)
having a ratio r=CC0/IC100, i.e., ratio of concentration CC0 at which survival of MT-4 cells is decreased upon cell proliferation tests to concentration IC100 at which HIV-1-induced cytopathic effect (CPE) on MT-4 cells is inhibited by 100%, of 2 or more and
having a protein kinase C(PKC) activation of 30% or less at a concentration of 10 ng/mL.
The agent is useful as an anti-HIV agent.
Abstract: An anti-inflammatory analgesic patch containing loxoprofen, crotamiton, solvent, skin permeation accelerator, water-soluble polymers and moisturizers. The patch allows for the loxoprofen to penetrate the skin.
Abstract: An external preparation containing tranilast which is excellent in the release of the active ingredient contained therein, achieves a high percutaneous absorption, fully ensures the effective drug concentration in the skin tissue and little irritates the skin This preparation is composed of an aqueous base containing as the active ingredient tranilast, its salt or a mixture thereof. The aqueous base contains a solubilizer for tranilast, a dispersant, an absorption aid, an adhesive and/or a shape retenting agent, and water. The active ingredient has been solubilized by the above-mentioned solubilizer and dispersed in the aqueous base by the above-mentioned dispersant.
Type:
Grant
Filed:
August 4, 1998
Date of Patent:
May 29, 2001
Assignees:
Lead Chemical Co., Ltd., Kissei Pharmaceutical Co., Ltd.
Abstract: Compounds including 1-(biphenyl-4-yl)methyl-1H-1,2,4-triazoles and 1-(biphenyl-4-yl)methyl-4H-1,2,4-triazoles each having a (2,4-dioxopyrrolidine-5-ylidene)methyl or (2,4-dioxo-tetrahydrofiuran-5-ylidene)methyl group as the substituent at the 2′-position and salts thereof are lowly toxic and highly safe and are useful as an angiotensin II antagonist. Thus, these compounds can be used in medicines, which contain these compounds as an active ingredient.
Abstract: A release controlled transdermal therapeutic system having excellent storage stability and capable of optionally controlling the release rate of drugs, comprising a rubbery adhesive, microcapsules comprising a water-soluble wall material and encapsulating drugs as core material, and a water-insoluble, rubber- and rubber solvent-insoluble, water absorbing resin powder, such as starch-polyacrylic acid salt copolymers, the microcapsules and the resin powder being dispersed in the rubbery adhesive.